Long-Term Efficacy and Safety of Lerodalcibep in Children and Adolescents With Familial Hypercholesterolemia

Inclusion Criteria: 1. Provision of written and signed informed consent/assent of the LIB003-016 trial prior to any study-specific procedure; 2. Completion of the LIB003-008 study having received the last dose of study drug at Week 20 and completed the Week 24 visit; 3. Male or female, 6 to 17 years of age (defined as from 6 to less than 18 years of age), at the first Screening Visit of the LIB003-008 study; 4. Weight of \>18 kg (40 lbs) and BMI \<17 and \>42 kg/m2; 5. On stable diet and lipid-lowering oral drug therapy (statins, ezetimibe, bile-acid sequestrants) or combinations thereof (excluded oral lipid-lowering agents are include mipomersen, lomitapide, and gemfibrozil); Exclusion Criteria: 1. History of any prior or active clinical condition or acute and/or unstable systemic disease compromising patient inclusion, at the discretion of the Investigator, which in the Investigator's opinion, would not be suitable for the study from a patient safety consideration or could interfere with the results of the study; 2. Females of childbearing potential who are sexually active, not using or unwilling to use a highly effective form of contraception during the study and until 60 days after last dose of study drug, pregnant or breastfeeding, or who have a positive urine pregnancy test at the last Screening Visit; 3. Patients who cannot be available for Protocol-required study visits or procedures, to the best of the patient's and Investigator's knowledge; 4. A history, during the LIB003-008 study of prescription drug abuse, illicit drug use, or alcohol abuse according to medical history; 5. Have any other finding which, in the opinion of the Investigator, would compromise the patient's safety or participation in the study;